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Abstract
Insulin-like Growth Factor 1 (IGF-1) has broad-range neuroprotective effects and is a therapeutic candidate for Huntington’s disease (HD). IGF-1
protects striatal neurons from the toxicity of mutated huntingtin in vitro and improves neuronal survival in vivo in a phenotypic model of HD involving
excitotoxic cell death. Because HD is a multifactorial disease, it is important to evaluate the neuroprotective role of IGF-1 in other pathological
situations involved in HD progression. We have evaluated the neuroprotective effects of IGF-1 in vivo, using the 3-nitropropionic acid (3NP) rat
model which replicates the mitochondrial dysfunction observed in HD. Continuous intracerebroventricular infusion of recombinant IGF-1 at a low
dose (0.025g/h for 5 days) did not alleviate motor impairment and weight loss induced by 3NP treatment. In addition, histological evaluation
and quantification of DNA fragmentation evidenced no improvement in neuronal survival. Of interest, we found that a higher concentration of
IGF-1 (0.25g/h) resulted in an exacerbation of 3NP toxicity on striatal neurons. These results suggest that intracerebral delivery of IGF-1 may
not provide a fully effective therapeutic strategy for HD or other disorders involving mitochondrial impairment.
© 2007 Elsevier Ireland Ltd. All rights reserved.
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Huntington’s disease (HD) is an inherited neurodegenerative dis-
ease characterized by the preferential death of striatal neurons.
HD patients exhibit progressive motor, psychiatric and cognitive
abnormalities, and usually die within 10–20 years. The mutation
responsible for HD was identified more than 10 years ago as an
expanded polyglutamine tract in the N-terminal part of a pro-
tein named huntingtin (Htt) [27]. In spite of this well-defined
molecular alteration, HD appears as a highly complex and mul-
tifactorial disease [17]. Many factors have been implicated in
the degeneration of striatal neurons in HD including excitotoxi-
city, oxidative stress, protein misfolding as well as alterations in
Ca2+ homeostasis, transcription, intracellular signaling, axonal
transport and synaptic transmission [17]. Impairment in energy
metabolism and mitochondrial defects also seems to play a cen-
tral role in HD pathogenesis [7].
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Metabolic alterations in HD are evidenced by the fact that
patients are cachexic and exhibit striatal hypometabolism as well
as increased lactate levels before marked atrophy of the striatum
[6]. Recent studies in patients and genetic models of HD have
evidenced several mitochondrial anomalies involved in disease
progression [1,4,25]. These include preferential defects in mito-
chondrial complex II (succinate dehydrogenase, SDH) [4,25],
which is consistent with the observation that intoxication of
rodents and primates with 3-nitropropionic acid (3NP), an irre-
versible inhibitor of SDH, reproduces several histopathological
and clinical features of HD [7].
There is currently no effective treatment for HD despite
intense efforts to develop alternative therapeutic strategies. The
3NP models do not reproduce the genetic mutation responsi-
ble for HD. However, unlike transgenic models of HD, they
involve a marked degeneration of the striatum that makes them
valuable tools to evaluate neuroprotective strategies [7]. So
far, these models have allowed for the assessment of several
neuroprotective approaches such as inhibition of glutamate sig-
naling [24], supplementation with energetic substrates [22],
0304-3940/$ – see front matter © 2007 Elsevier Ireland Ltd. All rights reserved.
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inhibition of proteases [5], and gene transfer of neurotrophic
factors [23].
Along these lines, insulin-like growth factor 1 (IGF-1) is an
interesting neuroprotective candidate for HD. IGF-1 reduces the
toxicity of mutated Htt towards striatal neurons by inducing its
phosphorylation [16]. In addition, we have previously shown
that an intracerebroventricular (i.c.v.) infusion of recombinant
IGF-1 has neuroprotective effects against excitoxicity using the
quinolinate rat model of HD [12]. Here, we aimed to further
evaluate neuroprotective effects of IGF-1 in the 3NP rat model
of HD.
Three-month-old male Lewis rats (weighing ∼400 g, IFFA
Credo, France) were used. For surgical procedure, animals
were anesthetized with a mixture of ketamine (15 mg/kg) and
xylazine (1.5 mg/kg). All experimental procedures were car-
ried out in compliance with the recommendations of the EEC
(86/609/EEC) and the guidelines of the French National Com-
mittee (87/848) for the care and use of laboratory animals. All
chemicals were purchased from Sigma (Saint-Louis, MO) unless
otherwise specified.
On day 0, rats were simultaneously implanted in the left
lateral ventricle with a canula connected to a minipump filled
with either IGF-1 at 0.025g/l (n = 10), IGF-1 at 0.25g/l
(n = 10) or vehicle (n = 10) and with a subcutaneous pump filled
with 3NP. Additional controls included sham-operated animals
(n = 9).
On days 4 and 5, rats were evaluated using a clinical index
as described previously (normal = 0, very symptomatic = 8) [23].
On day 5, animals were killed by decapitation, and the brain was
rapidly removed from the skull. The left hemisphere was frozen
in isopentane, and used for histochemistry to assess the activi-
ties of cytochrome oxidase (COX) and succinate dehydrogenase
(SDH). The striatum and somatosensory cortex were dissected
out from the right hemisphere in five animals per group for the
purpose of biochemical analysis (quantification of IGF-1 and
free oligonucleosomes levels).
Lyophilized recombinant human IGF-1 (R&D systems Inc.,
Minneapolis, MN) was dissolved to a final concentration of 0.25
and 0.025g/l in a vehicle composed of 10 mM acetic acid
with 0.1% bovine serum albumin in 0.1 M phosphate buffer
saline (PBS). Continuous i.c.v. delivery of IGF-1 was made via
an osmotic minipump (1l/h, 2001 model, Alzet, Palo Alto,
CA) connected to a canula (stereotaxic coordinates: Antero-
posterior, −0.7 mm; lateral, 1.5 mm left from bregma; ventral,
3.6 mm from dura with tooth bar set at −3.3 mm; “brain infu-
sion kit”, Alzet) which was secured to the skull bone with dental
cement as previously described [5]. Previous experiments have
shown that IGF-1 degradation in the minipump was minimal, at
least during the first 2 days after implantation [12].
3NP (Fluka, Saint-Louis, MO) was prepared as previ-
ously described and systemically administered via subcutaneous
osmotic pumps (2ML1 model, Alzet) delivering 56 mg/kg/day
for 5 days [5]. Control rats (no 3NP treatment) were similarly
anesthetized and subject to identical surgical procedures. One rat
of the group receiving the highest dose of IGF-1 was found dead
on day 5 and was excluded for the calculation of the behavioral
score at day 4.
The lateral striatum and the somatosensory cortex were
rapidly dissected out from acutely prepared coronal sections
(2 mm thick) prepared with a steel rat-brain matrix. Tissue sam-
ples were homogenized using a 1 ml glass–Teflon-homogenizer
(900 rpm, 20 strokes) in 300l of buffer (25 mM HEPES pH 7.6,
0.1% Triton X-100, 5 mM MgCl2, 1.3 mM EDTA, 1 mM EGTA,
with protease inhibitor cocktail “complete”, Roche, Indianapo-
lis, IN). Homogenates were pooled by experimental group and
centrifuged at 10,000 × g for 30 min at 4 ◦C. The supernatant
was collected and stored at −80 ◦C until analysis.
Striatal and cortical supernatants were used for the quan-
tification of IGF-1 concentrations using the Quantikine Human
IGF-1 colorimetric Sandwich ELISA kit (R&D) as described
previously [12]. Quantification was made in duplicate for each
group and each cerebral region.
Striatal supernatants were used for the quantification of free
oligonucleosomes using the Cell Death detection ELISA plus
kit (Roche) [5]. The measure was made in triplicate and was
normalized to the protein content of each sample as measured
by the microBCA kit (Pierce, Rockford, IL).
The left frozen hemispheres were cut serially into 40m-
thick sections using a cryostat and stored at –20 ◦C before
histochemistry. For each animal, 10–12 serial sections encom-
passing the striatum were examined (interspace 400m).
SDH and COX histochemistry were performed as previously
described, to quantify the regional Vmax of these enzymes [5,14].
Non-specific staining was evaluated by incubating adjacent
sections without substrate (succinate and cytochrome c, respec-
tively). To precisely evaluate the loss of striatal COX activity
due to striatal neurodegeneration, striatal COX activity was nor-
malized to COX activity in the cortex, because cortical cells are
generally unaffected by 3NP treatment.
Sections labeled for COX histochemistry were also used to
evaluate the volume of striatal lesions. Lesioned areas were mea-
sured by delineating the external border of the lesion seen as a
pale staining on digitized images. From these areas, the volume
of the striatal lesion was determined using the Cavalieri method
as previously described [12].
The blood was collected from decapitated animals and the
plasma was recovered by a 3 min centrifugation at 3000 rpm.
Samples were stored at −80 ◦C until analysis. Plasma glucose
concentrations were measured using the glucose oxidase method
(Beckman Coulter, Fullerton, CA, USA).
Results are expressed as mean values ± S.E.M. Statisti-
cal analysis included one-way analysis of variance (ANOVA)
followed by a post-hoc Scheffe´’s test. Motor scores were com-
pared using non-parametric tests: Kruskall–Wallis followed by
a U Mann–Whitney test. The level of significance was set
at p < 0.05.
On day 5 of 3NP treatment, IGF-1 concentration was quan-
tified in striatal and cortical homogenates. 3NP treatment
associated with an i.c.v. infusion of the vehicle did not alter
IGF-1 basal concentrations (p > 0.6 between Control and vehi-
cle groups). Chronic infusion of IGF-1 at a rate of 0.025
and 0.25g/h in the lateral ventricle increased IGF-1 striatal
concentration by 30% and 144%, respectively (Table 1). A sig-
nificant increase in IGF-1 concentration was also detected in the
Author's personal copy
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Table 1
I.C.V. infusion of IGF-1 increases striatal and cortical IGF-1 concentrations
Control Vehicle IGF-1 0.025g/h IGF-1 0.25g/h
[IGF-1] pg/mg total protein
Striatum 49.6 ± 0.4 50.2 ± 0.2 64.7 ± 1.4a 122.8 ± 0.5b
Cortex 35.8 ± 1.1 37.8 ± 0.9 42.7 ± 0.9c 59.2 ± 0.9a
ELISA measurement of IGF-1 in striatal and cortical extracts after 5 days of an i.c.v. infusion of IGF-1 at 0.025 or 0.25g/h or vehicle. Brain IGF-1 levels were
significantly increased by infusion of recombinant IGF-1 at both concentrations. Measurements were made in duplicate and expressed as mean values ± S.E.M.
a p < 0.005 vs. control and vehicle groups.
b p < 0.0001 vs. control, vehicle and IGF-1 at 0.025g/h groups.
c p < 0.05 vs. control and IGF-1 at 0.25g/h groups, ANOVA and Scheffe´’s test.
somatosensory cortex (+20% and 64% for a delivery dose of
0.025 and 0.25g/h, respectively, Table 1).
To check that the i.c.v. infusion of IGF-1 did not directly inter-
fere with 3NP and its inhibition of the mitochondrial enzyme
SDH, SDH activity was measured on brain slices by histo-
chemistry at the end of 3NP treatment. Optical densities were
measured in the unlesioned somatosensory cerebral cortex, to
have an index of SDH inhibition independent of SDH depletion
due to neuronal death [5]. Treatment with 3NP led to a signifi-
cant inhibition of SDH activity in the cerebral cortex (p < 0.0001
versus control). Levels of SDH inhibition were similar in all
3NP-treated groups (p = 0.9 and 0.1 between vehicle and IGF-1
at 0.025 and 0.25g/h, respectively), demonstrating that IGF-1
did not directly interfere with 3NP. We then evaluated IGF-1 neu-
roprotective effects against metabolic impairment using clinical,
histological and biochemical indices.
Chronic treatment with 3NP leads to a sustained metabolic
inhibition associated with a progressive weight loss. At day 5
of 3NP treatment, animals in all 3NP-treated groups had weight
loss, but the decrease in body weight was significantly exacer-
bated in the group receiving the highest dose of IGF-1 (Fig. 1A).
Sham-operated animals had stable body weight over the entire
5-day period (data not shown).
Chronic 3NP treatment also induced progressive motor
impairment (dystonia, dyskinesia and hypokinesia) which was
quantified by a behavioral scale. Progressive motor disabil-
ities were first detected in all groups after 4 days of 3NP
infusion. IGF-1 at the lowest dose tested (0.025g/h) had
no detectable effect compared to vehicle (Fig. 1B). In the
group receiving 0.25g/h IGF-1, motor disabilities were sig-
nificantly exacerbated at day 5 (p < 0.001 versus vehicle and
0.025g/h IGF-1).
To evaluate the effects of IGF-1 on the survival of striatal neu-
rons, we first evaluated the activity of the mitochondrial enzyme
COX, a sensitive index of neuronal integrity, using histochem-
istry [5,14]. Rats treated with 3NP had a visible lesion in the
striatum, characterized by low COX activity (Fig. 2A). Cortical
COX activity was not affected by either 3NP or IGF-1 (p = 0.39,
data not shown). Conversely, striatal COX activity was signifi-
cantly decreased in all 3NP treated groups (Fig. 2B). However,
animals receiving 0.25g/h IGF-1 displayed exacerbated loss
of striatal COX activity (Fig. 2B). The highest dose of IGF-1
also resulted in a significant increase in the size of striatal lesion
while IGF-1 at low doses did not have any significant effect
compared with vehicle (Fig. 2C).
Additionally, we measured levels of free oligonucleosomes
in striatal extracts at the end of 3NP treatment as an index of
ongoing cell death. Treatment with 3NP induced significant
increases in free oligonucleosomes compared with control ani-
mals (Fig. 2D). Levels of free oligonucleosomes were further
increased in 3NP-treated rats receiving IGF-1 at both doses
(Fig. 2D).
Because IGF-1 is involved in the regulation of peripheral
energy metabolism [15], we measured blood glucose levels at the
end of 3NP treatment. IGF-1 at 0.25g/h significantly increased
blood glucose levels compared to controls (Fig. 2E).
Fig. 1. IGF-1 exacerbates 3NP effects on weight loss and motor symptoms. (A)
Rat infused with IGF-1 at 0.25g/h lost more weight during 3NP treatment.
*p < 0.05 vs. vehicle and IGF-1 at 0.025g/h, ANOVA followed by Scheffe´’s
test. (B) The severity of motor symptoms was evaluated at day 4 (D4) and day
5 (D5) of 3NP treatment using a motor score. Rats receiving IGF-1 at 0.25g/h
exhibit more significant motor deficits. IGF-1 at 0.025g/h has no benefi-
cial effects. **p < 0.001 vs. vehicle and IGF-1 at 0.025g/h, Kruskall–Wallis
followed by U Mann–Whitney test.
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Fig. 2. IGF-1 increases 3NP-mediated neuronal death in the striatum and alters glycemia. (A) Images of representative brain sections stained for COX histochemistry
of control rats (Ctr) and rats chronically treated with 3NP and receiving vehicle (Veh), IGF-1 at 0.025 and 0.25g/h. The lesion, delimited by black arrows, appears
larger with the highest dose of IGF-1. (B) COX activity was quantified by densitometry and expressed as a ratio between striatal and cortical COX activities.
3NP treatment induces a significant decrease in COX activity due to striatal lesion. **p < 0.01 vs. control group (Ctr) #p < 0.05 vs. vehicle group (Veh), ANOVA
and Scheffe´’s test. (C) Lesion sizes were quantified at the end of 3NP treatment on serial sections stained for COX histochemistry. IGF-1 at 0.25g/h significantly
increases the size of the lesion. At lower doses, IGF-1 tended to reduce the lesion induced by 3NP compared to vehicle (Veh), without reaching significance. *p < 0.05,
ANOVA and Scheffe´’s test. (D) The striatal content in free oligonucleosomes was assessed at the end of 3NP treatment. 3NP significantly increases the level of
free oligonucleosomes in all groups. IGF-1 significantly exacerbates this effect at both concentrations. **p < 0.001, ***p < 0.0001 vs. control group (Ctr). #p < 0.05
vs. vehicle group (Veh). ANOVA and Scheffe´’s test. (E) Blood glucose levels were measured at the end of 3NP treatment. The highest dose of IGF-1 resulted in
hyperglycemia. *p < 0.01 vs. control group. ANOVA and Scheffe´’s test.
Several arguments support the therapeutic use of IGF-1 in
HD. IGF-1 is a neurotrophic factor with broad-range neuropro-
tective effects [11], and specifically protects cultured striatal
neurons exposed to mutated Htt [16]. In addition, IGF-1, which
belongs to the insulin family, is involved in the regulation
of peripheral and central energy metabolism [15], both of
which have been identified as abnormal in HD patients [28].
Specifically, patients and transgenic HD mice commonly suf-
fer from hyperglycemia that may be attributable to decreased
insulin production or sensitivity [13,18]. In addition to protect-
ing neurons, IGF-1 may thus restore normal insulin signaling,
reverse hyperglycemia and improve the metabolic status of HD
patients.
We found that IGF-1 at low doses was ineffective at prevent-
ing cell death and, at high doses, was toxic for striatal neurons
subjected to impairment of energy metabolism. The absence of
neuroprotective effects of 0.025g/h IGF-1 was unlikely due
to an insufficient striatal concentration of IGF-1, because we
found increased levels of free oligonucleosomes at this dose.
This observation also suggests that while low doses of IGF-1
do not increase lesion volume, they exacerbate the severity of
neurodegenerative processes.
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Increasing IGF-1 striatal concentrations to twice the control
level (5-day infusion of IGF-1 at 0.25g/h) exacerbated 3NP-
induced weight loss, motor disabilities, and cell death in the
lateral striatum. Importantly, the level of 3NP-mediated inhi-
bition of SDH was similar in all groups, ruling out a direct
interaction of IGF-1 with 3NP. It rather seems that chronic
i.c.v. infusion of IGF-1 selectively increases the vulnerability
of the striatum to 3NP. We have previously shown that the
same delivery system of IGF-1 was neuroprotective against an
intrastriatal injection of the NMDA receptor agonist quinoli-
nate, which triggers excitotoxic processes and Ca2+ overload
[12]. Excitotoxicity and Ca2+ deregulation are also involved in
the 3NP-mediated neuronal death. However, they are thought
to result from an altered ability of mitochondria subjected
to metabolic impairment to buffer Ca2+ getting into neurons
through NMDA receptors [19]. Therefore, it is likely that 3NP
and quinolinate contribute to neuronal death via different mech-
anisms, which may explain why IGF-1 is protective against
quinolinate and not 3NP, as reported for other neuroprotective
agents such as minocycline [2].
IGF-1 plays a key role in several physiological functions such
as growth and metabolic regulation [29]. Concentration of IGF-
1 in the brain is relatively low, while it can be released at high
levels from the liver after stimulation by the growth hormone
produced by the pituitary gland [26]. As IGF-1 exerts a nega-
tive feedback on the hypothalamo-pituitary axis [26], a chronic
i.c.v. delivery of IGF-1 may alter the equilibrium between cen-
tral and peripheral IGF-1 concentrations, leading to general
metabolic disturbances, as supported here by the development of
hyperglycemia. IGF-1 protoxic effects in presence of metabolic
impairment may therefore result from peripheral and/or central
effects. Further studies should evaluate the precise mechanisms
involved.
Other delivery modes of IGF-1 to the nervous system such
as intranasal infusion [21], diffusion from subcutaneous micro-
spheres [8] or viral gene transfer [20] have proven efficient
and may represent useful alternative strategies. IGF-1 levels are
also increased by physical exercise, which may lead to a more
physiological upregulation of IGF-1 cerebral concentrations
[9].
IGF-1 has been proposed to be a therapeutic candidate
for amyotrophic lateral sclerosis [20] and Alzheimer’s disease
[10], two neurodegenerative diseases characterized by metabolic
disturbances [3]. It is therefore important to evaluate IGF-1
neuroprotective potential in animal models which reproduce
metabolic defects found in patients and to test alternative modes
of delivery of IGF-1 to the brain. Our results suggest that a cen-
tral delivery of IGF-1 might not be beneficial in pathological
conditions associated with impairment in energy metabolism.
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